Stay in touch!
img-9

Binosto

Binosto is a buffered, soluble, effervescent alendronate tablet formulation that addresses the challenges of gastrointestinal (GI) tolerability and patient adherence to bisphosphonates1,2

While oral bisphosphonates have broad-spectrum efficacy to reduce fragility fractures, persistence is crucial.2,3 2 in 3 postmenopausal women in the UK discontinue oral bisphosphonate therapy within a year.4

Binosto is indicated for the treatment of postmenopausal osteoporosis. It reduces the risk of vertebral and hip fractures.5

Additionally, Binosto benefited from a 36% list price reduction to support the NHS1,2*

Binosto Prescribing Information

* Price reduction live from July 2021. Available at: amims.co.uk/drugs/endocrine/
osteoporosis-other-bone-disorders/binosto Accessed November 2023.

Fully soluble, buffered, Binosto enhances upper GI tolerability, supporting persistence.1,2

thumb

Avoids solid bisphosphonate irritating the oesophageal mucosa6,7

Gastric pH levels are rapidly buffered to >3, lessening the risk of damage if reflux occurs6,7

thumb

Fewer patients discontinued treatment due to GI adverse events with Binosto than with conventional alendronate tablets2

thumb

Significantly increased persistence vs conventional alendronate tablets2

thumb

Persistence rate of 81% reported in real-world patients at 1 year2

thumb

Dissolves in just half a glass of plain water (120 ml)5

img-10

Patient Guide download

Please register for an instant download of the Binosto Patient Guide. The guide will provide more information for patients on Binosto, how to take it, osteoporosis and tips on how to manage their condition.

Register to download

HCP Information Guide download

Please register for an instant download of our Binosto HCP Information Guide. The guide offers information on key benefits, support and background for buffered, soluble, effervescent alendronate tablet formulation.1,2

Register to download
shape-3
References
  1. Minisola S et al. JBMR Plus 2021; 5(7): e10510.
  2. Giusti A et al. Aging Clin Exp Res 2021; 33(9): 2529-37.
  3. Bastounis A et al. Osteoporos Int 2022; 33(6): 1223-33.
  4. Morley J et al. Osteoporos Int 2020; 31(3): 533-45.
  5. Binosto 70 mg Effervescent Tablets Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7113. Accessed: November 2023.
  6. Fuggle N et al. Aging Clin Exp Res 2022; 34(11): 2625-34.
  7. Hodges LA et al. Int J Pharm 2012; 432(1-2): 57-62.
Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164

UK-MULT-130c(3)     |     Date of Preparation November 2023

footer-logo

Thornton & Ross is a member of the STADA Group © Copyright Thornton & Ross 2023